Scott Wilkinson, Anson T Ku, Rosina T Lis, Isaiah M King, Daniel Low, Shana Y Trostel, John R Bright, Nicholas T Terrigino, Anna Baj, John M Fenimore, Chennan Li, BaoHan Vo, Caroline S Jansen, Huihui Ye, Nichelle C Whitlock, Stephanie A Harmon, Nicole V Carrabba, Rayann Atway, Ross Lake, Haydn T Kissick, Peter A Pinto, Peter L Choyke, Baris Turkbey, William L Dahut, Fatima Karzai, Adam G Sowalsky
Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence, and the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult micrometastatic disease by their addition to definitive treatment. Sufficient profiling of baseline disease has remained a challenge in enabling the in-depth assessment of phenotypes associated with exceptional vs. poor pathologic responses after treatment. In this study, we report comprehensive and integrative gene expression profiling of 37 locally advanced prostate tumors prior to six months of androgen deprivation therapy (ADT) plus the androgen receptor (AR) inhibitor enzalutamide prior to radical prostatectomy...
February 11, 2024: medRxiv